Диссертация (1140670), страница 25
Текст из файла (страница 25)
– 2010. – Vol. 53. – № 11.– P. 931–935.112.Kimura, Y. Pulmonary hypertension and other potentially fatal pulmonarycomplications in systemic juvenile idiopathic arthritis / Y. Kimura // ArthritisCare Res (Hoboken). – 2013. – Vol. 65. – № 5. – P. 745–752.113.Klein, A. Efficacy and safety of oral and parenteral methotrexate therapy inchildren with juvenile idiopathic arthritis. An observational study with patientsof the German Methotrexate Registr / A. Klein [et al.] // Arthritis Care Res.(Hoboken).
– 2012. – Vol. 64. – № 9. – P. 1349–1356.114.Krause, M.L. Juvenile Idiopathic Arthritis in Olmsted County, Minnesota,1960–2013 / M.L. Krause // Arthritis Rheumatol (Hoboken, N.J.). – 2016. –Vol. 68. – № 1. – P. 247–254.115.Kuna, A.T. Antibodies to mutated citrullinated vimentin and antibodies to cycliccitrullinated peptides in juvenile idiopathic arthritis / A.T.
Kuna // Clin. Chem.Lab. Med. – 2009. – Vol. 47. – № 12. – P. 1525–1530.116.Lanni S. и др. Outcome and predicting factors of single and multiple intra–articular corticosteroid injections in children with juvenile idiopathic arthritis //Rheumatology. 2011.– Vol. – 50. № 9.– P. 1627–1634.117.Lanni, S. Towards a role of ultrasound in children with juvenile idiopathicarthritis / S. Lanni // Rheumatology (Oxford). – 2013. – Vol. 52.
– № 3. – P.413–420.118.Lehman, T. Administration warning of malignancy in children receiving tumornecrosis factor alpha blockers change the way we treat children with juvenileidiopathic arthritis? / T. Lemn // Arthritis Rheum. – 2010. – № 62. – P. 2183–2184.119.Len, C. Gastroduodenal lesions in children with juvenile rheumatoid arthritis / /Len [et al.] // Hepatogastroenterology. – 1999. – Vol. 46. – № 26. – P. 991–996.120.Lovell, D.J.
Adalimumab with or without methotrexate in juvenile rheumatoid148arthritis / D.J. Lovell [et al.] // N. Engl. J. Med. – 2008. – Vol. 359. – № 8. – P.810–820.121.Lovell, D.J. Etanercept in children with polyarticular juvenile rheumatoidarthritis. Pediatric Rheumatology Collaborative Study Group / D.J. Lovell [etal.] // N. Engl. J. Med. – 2000. – Vol. 342. – № 11. – P. 763–769.122.Luca, N.J.C., Feldman, B.M. Health outcomes of pediatric rheumatic diseases /N.J.C.
Luca, B.M. Feldman // Best Pract. Res. Clin. Rheumatol. – 2014.– Vol.28. – № 2. – P. 331–350.123.Macaubas, C. Oligoarticular and polyarticular JIA: epidemiology andpathogenesis / C. Macaubas // Nat. Rev. Rheumatol. – 2009. – Vol. 5. – № 11.–P. 616–626.124.Marieke, H Otten, Janneke Anink, Sandra Spronk. Efficacy of biological agentsin juvenile idiopathic arthritis: a systematic review using indirect comparisons /H. Marieke // Ann Rheum Dis.
– 2013. – Vol. 72. – P. 1806–1812.125.McQueen, F.M. Bone marrow edema and osteitis in rheumatoid arthritis: theimaging perspective / F.M. McQueen // Arthritis Res. Ther. – 2012. – Vol. 14. –№ 5. – P. 224.126.Miller, J. Sibling Exposure and Risk of Juvenile Idiopathic Arthritis / J.
Miller[et al.] // Arthritis Rheumatol (Hoboken, N.J.). – 2015. – Vol. 67. – № 7. – P.1951–1958.127.Moncrieffe, H. A subgroup of juvenile idiopathic arthritis patients who respondwell to methotrexate are identified by the serum biomarker MRP8/14 protein /H. Moncrieffe [et al.] // Rheumatol (United Kingdom). – 2013. – Vol. 52. – №8.
– P. 1467–1476.128.Mondal, R. Growth of children with juvenile idiopathic arthritis / R. Mondal [etal.] // Indian Pediatr. – 2014. – Vol. 51. – № 3. – P. 199–202.129.Mouy, R. Efficacy of cyclosporine A in the treatment of macrophage activationsyndrome in juvenile arthritis: report of five cases / R. Mouy // J Pediatr. –1996. – Vol.129(5). – P. 750–754.149130.Müller, L.–S.O. The paediatric wrist revisited: redefining MR findings inhealthy children / L.–S.O.
Müller [et al.] // Ann. Rheum. Dis. 2011. – Vol. 70. –№ 4. – P. 605–610.131.Nielsen, S. Preliminary evidence that etanercept may reduce radiographicprogression in juvenile idiopathic arthritis / S. Nielsen // Clin. Exp. Rheumatol.– 2008. – Vol. 26. – № 4. – P. 688–692.132.Nigrovic, P.A. Anakinra as first–line disease–modifying therapy in systemicjuvenile idiopathic arthritis: Report of forty–six patients from an internationalmulticenter series / P.A. Nigrovic // Arthritis Rheum. – 2011.
– Vol. 63. – № 2.– P. 545–555.133.Nordstrom, B.L. Risk of malignancy in children with juvenile idiopathicarthritis not treated with biologic agents / B.L. Nordstrom // Arthritis Care Res(Hoboken). – 2012. – Vol. 64. – № 9. – P. 1357–1364.134.Papadopoulou, C. Delineating the role of multiple intraarticular corticosteroidinjections in the management of juvenile idiopathic arthritis in the biologic era /C. Papadopoulou // Arthritis Care Res. – 2013. – Vol.
65. – № 7. – P. 1112–1120.135.Pascual, V. Role of interleukin–1 (IL–1) in the pathogenesis of systemic onsetjuvenile idiopathic arthritis and clinical response to IL–1 blockade / V. Pascual// J. Exp. Med. – 2005. – Vol. 0201. – № 9. – P. 1479–1486.136.Pedersen, R.C., Person, D.A. Cerebral vasculitis in an adolescent with juvenilerheumatoid arthritis / R.C. Pedersen, D.A. Person // Pediatr. Neurol. – 1998.–Vol.
19. – № 1. – P. 69–73.137.Petty, R.E., Smith, J.R., Rosenbaum, J.T. Arthritis and uveitis in children: Apediatric rheumatology perspective / R.E. Petty, J.R. Smith, J.T. Rosenbaum //Am. J. Ophthalmol. – 2003. – Vol. 135. – № 6. – P. 879–884.138.Petty, R.E., Southwood, T.R., Manners, P., Baum, J., Glass, D.N., Goldenberg,J. International League of Associations Rheumatology classification of juvenileidiopathic arthritis: second revision, Edmonton, 2001 / R.E. Petty, T.R.150Southwood, P. Manners [et al.] // J Rheumatol. – 2004. – Vol. 31. – P.
390–392.139.Pohjankoski, H. Simultaneous juvenile idiopathic arthritis and diabetes mellitustype 1 –– a Finnish nationwide study / H. Pohjankoski [et al.] // J. Rheumatol. –2012. – Vol. 39. – № 2. – P. 377–381.140.Prince, F.H.M. Major improvements in health–related quality of life during theuse of etanercept in patients with previously refractory juvenile idiopathicarthritis / F.H.M. Prince [et al.] // Ann. Rheum. Dis. – 2010.
– Vol. 69. – № 1. –P. 138–142.141.Quartier, P. A multicentre, randomised, double–blind, placebo–controlled trialwith the interleukin–1 receptor antagonist anakinra in patients with systemic–onset juvenile idiopathic arthritis (ANAJIS trial) / P. Quartier [et al.] // Ann.Rheum. Dis. – 2011. – Vol. 70. – № 5.
– P. 747–754.142.Rathi, H. The Efficacy and Safety of Abatacept, Adalimumab, Etanercept AndTocilizumab are Comparable In Polyarticular Juvenile Idiopathic Arthritis / H.Rathi [et al.] // Value Heal. – 2015. – Vol. 18. – № 7. – P. A636.143.Ravelli, A. Antinuclear antibody–positive patients should be grouped as aseparate category in the classification of juvenile idiopathic arthritis / A. Ravelli[et al.] // Arthritis Rheum. – 2011. – Vol.63.
– № 1. – P. 267–275.144.Ravelli, A. Correlation between conventional disease activity measures injuvenile chronic arthritis / A. Ravelli [et al.] // Ann. Rheum. Dis. – 1997. – Vol.56. – № 3. – P. 197–200.145.Ravelli, A. Macrophage activation syndrome in systemic juvenile rheumatoidarthritis successfully treated with cyclosporine / A. Ravelli [et al.] // J. Pediatr.
–1996. – Vol. 128. – № 2. – P. 275–278.146.Reddy, V.V. Soluble CD25 in serum: A potential marker for subclinicalmacrophage activation syndrome in patients with active systemic onset juvenileidiopathic arthritis / V.V. Reddy [et al.] // Int. J. Rheum. Dis. – 2014. – Vol.17.– № 3. – P. 261–267.147.Robazzi, T.C. Autoimmune endocrine disorders and coeliac disease in children151and adolescents with juvenile idiopathic arthritis and rheumatic fever / T.C.Robazzi [et al.] // Clin.
Exp. Rheumatol. – 2013. – Vol. 31. – № 2. – P. 310–317.148.Rose, C.D. Epidemiology of juvenile rheumatoid arthritis in the Americas: anupdate / C.D. Rose [et al.] // J. Clin. Rheumatol. – 2006. – Vol. 12. – № 3. – P.129–130.149.Rossum, van M.A. Sulfasalazine in the treatment of juvenile chronic arthritis: arandomized, double–blind, placebo–controlled, multicenter study. DutchJuvenile Chronic Arthritis Study Group / M.A.
van Rossum [et al.] // ArthritisRheum. – 1998. – Vol. 41. – № 5. – P. 808–816.150.Ruperto, N. A randomized, placebo–controlled trial of infliximab plusmethotrexate for the treatment of polyarticular–course juvenile rheumatoidarthritis / N. Ruperto [et al.] // Arthritis Rheum. – 2007. – Vol.
56. – № 9. – P.3096–3106.151.Ruperto, N. Abatacept improves health–related quality of life, pain, sleepquality, and daily participation in subjects with juvenile idiopathic arthritis / N.Ruperto [et al.] // Arthritis Care Res (Hoboken). – 2010. – Vol. 62. – № 11. – P.1542–1551.152.Ruperto, N. Abatacept in children with juvenile idiopathic arthritis: arandomised, double–blind, placebo–controlled withdrawal trial / N. Ruperto [etal.] // Lancet. – 2008. – Vol. 372.
– № 9636. – P. 383–391.153.Ruperto, N. Cyclosporine A in juvenile idiopathic arthritis. Results of thePRCSG/PRINTO phase IV post marketing surveillance study / N. Ruperto [etal.] // Clin. Exp. Rheumatol. – 2006. – Vol. 24. – № 5. – P. 599–605.154.Ruperto, N. Long–term safety and efficacy of abatacept in children withjuvenile idiopathic arthritis / N.
Ruperto [et al.] // Arthritis Rheum. – 2010. –Vol. 62. – № 6. – P. 1792–1802.155.Ruperto, N., Murray, K. A randomized trial of parenteral methotrexatecomparing an intermediate dose with a higher dose in children with juvenile152idiopathic arthritis who failed to respond to standard doses of methotrexate / N.Ruperto [et al.] // Arthritis Rheum.
– 2004. – Vol. 50. – № 7. – P. 2191–2201.156.Salonen, P.H. Bloodstream infections among children with juvenile idiopathicarthritis: a prospective study from the onset of disease / P.H. Salonen [et al.] //Clin. Exp. Rheumatol. – 2014. – Vol. 32. – № 6.
– P. 979–983.157.Saurenmann, R.K. Epidemiology of juvenile idiopathic arthritis in a multiethniccohort: ethnicity as a risk factor / R.K. Saurenmann [et al.] // Arthritis Rheum. –2007. – Vol. 56. – № 6. – P. 1974–1984.158.Scott, C. A reappraisal of intra–articular corticosteroid therapy in juvenileidiopathic arthritis / C. Scott [et al.] // Clin. Exp. Rheumatol. – 2010. – Vol. 28.– № 5. – P. 774–781.159.Shepherd, J. The clinical effectiveness and cost–effectiveness of abatacept,adalimumab, etanercept and tocilizumab for treating juvenile idiopathicarthritis: a systematic review and economic evaluation / J. Shepherd [et al.] //Health Technol.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
